Endocision closes seed financing round to support regulatory clearance of its cryocatheter platform
MONTREAL, QUEBEC, — Endocision, a medical devices company in Montreal, Quebec, specializing in the development of minimally invasive cryogenic devices for diagnosis and treatment of lung diseases, has announced the successful closure of a seed equity funding round with participation from private investors and Investissement Quebec.
The funding will support the completion of development of its current device, a novel flexible cryobiopsy catheter for bronchoscopic Interstitial Lung Disease biopsies, and regulatory clearance to commercialize it in 2024. The funding has already enabled the company to grow its core team and will bolster further skilled job creation in the Montreal MedTech ecosystem. Endocision is led by Jean-Pierre Desmarais, formerly Chief Scientific Officer at CryoCath, which commercialized the first cryoablation catheter for atrial fibrillation treatment and was acquired by Medtronic in 2008.
“We are thrilled to have gathered the support of investors, the government, and preeminent physicians in interventional pulmonology and thoracic surgery as we work towards bringing our innovative technology to patients suffering from lung diseases,” said Jean-Pierre Desmarais, Chief Executive Officer at Endocision. “Our minimally invasive cryogenic devices have the potential to significantly improve access to interstitial lung disease biopsies and provide less invasive treatment options for patients. Our devices are also low cost and uniquely designed to be compatible with robotic bronchoscopy techniques, which will expand minimally invasive capabilities for pulmonologists and thoracic surgeons.”
Endocision’s proprietary technology uses cryogenic freezing to create a precise and controlled lesion. The flexible cryobiopsy catheter is designed to be operated and withdrawn independently from the scope, and can collect anatomical lung tissue samples for histological analysis, which currently would require an invasive and risky surgical procedure. The device is expected to offer a safer alternative, reducing risks and improving patient outcomes.
Endocision is a medical devices company founded in 2019 that is developing minimally invasive cryogenic devices for diagnosis and treatment of lung diseases, including interstitial lung disease (ILD) and lung cancer. Endocision is headquartered in Montreal, Quebec.